Effect of Selective Serotonin Reuptake Inhibitors in Alzheimer’s Disease with Comorbid Depression

Drugs & Aging ◽  
2012 ◽  
Vol 29 (10) ◽  
pp. 793-806 ◽  
Author(s):  
Amir A. Sepehry ◽  
Philip E. Lee ◽  
Ging Yuek R. Hsiung ◽  
B. Lynn Beattie ◽  
Claudia Jacova
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Serotonin Reuptake ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Serotonin Reuptake Inhibitors ◽  
Selective Serotonin ◽  
Comorbid Depression

scholarly journals Drug repurposing for Alzheimer’s disease: Selective serotonin reuptake inhibitors

2020 ◽  
Vol 16 (S9) ◽  
Author(s):  
Praveen P. Nekkar Rao ◽  
Gary Tin ◽  
Tarek Mohamed ◽  
Arash Shakeri ◽  
Amy Trinh Pham
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Serotonin Reuptake ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Drug Repurposing ◽  
Serotonin Reuptake Inhibitors ◽  
Selective Serotonin

Selective Serotonin Reuptake Inhibitors and Trazodone for Treatment of Depression, Psychosis, and Behavioral Symptoms in Patients With Dementia

2000 ◽  
Vol 12 (S1) ◽  
pp. 245-251 ◽  
Author(s):  
David L. Sultzer
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Adverse Effects ◽  
Serotonin Reuptake ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Serotonin Reuptake Inhibitors ◽  
Behavioral Symptoms ◽  
Selective Serotonin ◽  
Clinical Aspects ◽  
Treatment Of Depression

Depression, psychosis, agitation, and aggression are fundamental clinical aspects of Alzheimer's disease (AD) and other dementia syndromes. Although behavioral, environmental, and pharmacologic interventions often help ameliorate these symptoms, the efficacy of specific interventions is uncertain, and adverse effects of medications are common.

Sign in / Sign up

Export Citation Format

Share Document